This segment focuses on the research, development, and commercialization of topical products for dermatological conditions. Sienna Biopharmaceuticals is developing SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, currently in Phase IIb clinical trials for psoriasis and associated pruritus. The company also has SNA-125, a topical dual Janus kinase 3 inhibitor, in Phase I/II clinical trials for atopic dermatitis, psoriasis, and pruritus. Furthermore, SNA-001, a topical suspension of silver particles, is in pivotal clinical trials for acne treatment and light-pigmented hair reduction. The company utilizes advanced formulation technologies and clinical trial methodologies to address unmet needs in dermatology, aiming to improve patient outcomes and quality of life. The market positioning is focused on innovative solutions for common skin conditions, with potential for significant market share. Future opportunities include expanding the product pipeline and securing regulatory approvals. This segment is subject to rigorous clinical trial processes and FDA approval requirements.

This segment concentrates on developing therapies that target specific pathways in tissues, particularly the skin, to address immunological and inflammatory conditions. The primary focus is on developing treatments for psoriasis, atopic dermatitis, and associated pruritus. Research and development activities include identifying and validating drug targets, designing and synthesizing drug candidates, and conducting preclinical and clinical studies. The company utilizes advanced technologies such as small molecule inhibitors and topical formulations. The goal is to provide effective and safe treatments that reduce inflammation, alleviate symptoms, and improve the overall health of patients. Market positioning is based on providing innovative solutions for unmet medical needs in dermatology. Future opportunities include expanding the pipeline to include treatments for other inflammatory conditions. This segment is subject to regulatory oversight and requires successful completion of clinical trials.